New hope for leukemia patients allergic to key chemo drug
NCT ID NCT00590915
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study offers Erwinase, a different form of chemotherapy, to children and adults with acute lymphoblastic leukemia (ALL) who have had allergic reactions to standard L-asparaginase drugs. The goal is to provide a safe treatment option for those who cannot use the usual medications. Participants must have confirmed ALL and a history of allergic reactions to certain asparaginase formulations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- Can matching treatment to genetic risk beat relapsed childhood leukemia?
- Targeted drug aims to clear hidden leukemia before transplant
- Immunotherapy blinatumomab shows promise in kids with relapsed leukemia
- Researchers review CAR T-Cell results in kids with B-ALL
- Exercise during chemo: new study tests strength training for children with leukemia